1. Home
  2. WIX vs PBLS Comparison

WIX vs PBLS Comparison

Compare WIX & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wix.com Ltd.

WIX

Wix.com Ltd.

HOLD

Current Price

$73.90

Market Cap

3.2B

Sector

Technology

ML Signal

HOLD

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$31.20

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WIX
PBLS
Founded
2006
N/A
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.6B
IPO Year
2013
2026

Fundamental Metrics

Financial Performance
Metric
WIX
PBLS
Price
$73.90
$31.20
Analyst Decision
Buy
Analyst Count
22
0
Target Price
★ $134.67
N/A
AVG Volume (30 Days)
★ 1.3M
657.2K
Earning Date
05-13-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$15.80
N/A
Revenue Next Year
$13.21
N/A
P/E Ratio
$28.86
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$40.00
$25.56
52 Week High
$181.11
$42.49

Technical Indicators

Market Signals
Indicator
WIX
PBLS
Relative Strength Index (RSI) 45.76 35.58
Support Level $69.27 $26.42
Resistance Level $82.71 $33.65
Average True Range (ATR) 4.99 3.10
MACD -1.22 -0.94
Stochastic Oscillator 32.95 12.31

Price Performance

Historical Comparison
WIX
PBLS

About WIX Wix.com Ltd.

Wix.com is a software-as-a-service content management system platform that allows users to create, customize, and manage websites for themselves or for clients. Wix is best known for its Wix Editor service for self-creators, but in recent years, it has invested heavily and introduced its Wix Studio offering for partners, which are agencies and developers. Wix also offers a range of business solutions such as payment services and marketing products.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: